Found: 101
Select item for more details and to access through your institution.
Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1470328
- By:
- Publication type:
- Article
Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-37699-z
- By:
- Publication type:
- Article
Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-31248-w
- By:
- Publication type:
- Article
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13045-020-00953-8
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in China.
- Published in:
- Clinical & Translational Oncology, 2023, v. 25, n. 6, p. 1821, doi. 10.1007/s12094-023-03081-0
- By:
- Publication type:
- Article
The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics.
- Published in:
- BioMed Research International, 2015, v. 2015, p. 1, doi. 10.1155/2015/384575
- By:
- Publication type:
- Article
Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.1077768
- By:
- Publication type:
- Article
Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment.
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 1, doi. 10.1186/s13287-015-0164-4
- By:
- Publication type:
- Article
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, v. 16, p. 1, doi. 10.1177/17588359231221340
- By:
- Publication type:
- Article
Derivation and validation of a novel score for early prediction of severe CRS after CAR‐T therapy in haematological malignancy patients: A multi‐centre study.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 3, p. 517, doi. 10.1111/bjh.18873
- By:
- Publication type:
- Article
Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 4, p. 704, doi. 10.1111/bjh.18684
- By:
- Publication type:
- Article
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 1, p. 62, doi. 10.1111/bjh.18162
- By:
- Publication type:
- Article
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 5, p. 862, doi. 10.1111/bjh.17703
- By:
- Publication type:
- Article
Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 1, p. 126, doi. 10.1111/bjh.16951
- By:
- Publication type:
- Article
Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 1, p. 52, doi. 10.1111/bjh.16503
- By:
- Publication type:
- Article
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 5, p. 743, doi. 10.1111/bjh.14465
- By:
- Publication type:
- Article
Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.
- Published in:
- Journal of Translational Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12967-022-03798-6
- By:
- Publication type:
- Article
BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase.
- Published in:
- BMC Medical Genetics, 2017, v. 18, p. 1, doi. 10.1186/s12881-017-0381-z
- By:
- Publication type:
- Article
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 523, doi. 10.1002/ajh.27207
- By:
- Publication type:
- Article
The association of HLA-C alleles with multiple myeloma in Chinese patients.
- Published in:
- Experimental Hematology & Oncology, 2018, v. 7, n. 1, p. N.PAG, doi. 10.1186/s40164-018-0112-y
- By:
- Publication type:
- Article
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.
- Published in:
- Experimental Hematology & Oncology, 2017, v. 6, p. 1, doi. 10.1186/s40164-017-0081-6
- By:
- Publication type:
- Article
Targeting p53 via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma.
- Published in:
- PLoS ONE, 2012, v. 7, n. 1, p. 1, doi. 10.1371/journal.pone.0030215
- By:
- Publication type:
- Article
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).
- Published in:
- Annals of Hematology, 2024, v. 103, n. 4, p. 1305, doi. 10.1007/s00277-023-05573-z
- By:
- Publication type:
- Article
Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome: a case report and literature review.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 1, p. 339, doi. 10.1007/s00277-023-05465-2
- By:
- Publication type:
- Article
Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 11, p. 3195, doi. 10.1007/s00277-023-05427-8
- By:
- Publication type:
- Article
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
- Published in:
- Annals of Hematology, 2022, v. 101, n. 12, p. 2679, doi. 10.1007/s00277-022-04951-3
- By:
- Publication type:
- Article
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 6, p. 1201, doi. 10.1007/s00277-022-04795-x
- By:
- Publication type:
- Article
Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
- Published in:
- Annals of Hematology, 2015, v. 94, n. 2, p. 257, doi. 10.1007/s00277-014-2211-0
- By:
- Publication type:
- Article
Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation.
- Published in:
- Cancers, 2024, v. 16, n. 3, p. 498, doi. 10.3390/cancers16030498
- By:
- Publication type:
- Article
Intestinal Klebsiella pneumoniae Contributes to Pneumonia by Synthesizing Glutamine in Multiple Myeloma.
- Published in:
- Cancers, 2022, v. 14, n. 17, p. 4188, doi. 10.3390/cancers14174188
- By:
- Publication type:
- Article
Treatment and Prognosis of Adult T Cell Acute Lymphoblastic Leukemia.
- Published in:
- Acta Academiae Medicinae Sinica, 2019, v. 41, n. 4, p. 485, doi. 10.3881/j.issn.1000-503X.10807
- By:
- Publication type:
- Article
Analysis of Clinical Characteristics for 24 Cases of Nodal Marginal Zone Lymphoma.
- Published in:
- Acta Academiae Medicinae Sinica, 2017, v. 39, n. 2, p. 236, doi. 10.3881/j.issn.1000-503X.2017.02.012
- By:
- Publication type:
- Article
NEK2 induces autophagy‐mediated bortezomib resistance by stabilizing Beclin‐1 in multiple myeloma.
- Published in:
- Molecular Oncology, 2020, v. 14, n. 4, p. 763, doi. 10.1002/1878-0261.12641
- By:
- Publication type:
- Article
Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
- Published in:
- Advanced Science, 2022, v. 9, n. 9, p. 1, doi. 10.1002/advs.202104491
- By:
- Publication type:
- Article
Gemcitabine‐based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 2, p. 1, doi. 10.1002/cam4.6965
- By:
- Publication type:
- Article
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 4, p. 1043, doi. 10.1002/cam4.1337
- By:
- Publication type:
- Article
Multiple myeloma–derived miR‐27b‐3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment.
- Published in:
- Clinical & Translational Medicine, 2023, v. 13, n. 1, p. 1, doi. 10.1002/ctm2.1140
- By:
- Publication type:
- Article
Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β-Catenin Nuclear Enrichment.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.729799
- By:
- Publication type:
- Article
Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1184395
- By:
- Publication type:
- Article
Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1171539
- By:
- Publication type:
- Article
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 5, p. 1016, doi. 10.1002/ijc.34565
- By:
- Publication type:
- Article
Immunotherapy for multiple myeloma: new chances and hope.
- Published in:
- Cancer Biology & Medicine, 2023, v. 20, n. 10, p. 695, doi. 10.20892/j.issn.2095-3941.2023.0258
- By:
- Publication type:
- Article
Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
- Published in:
- Cancer Biology & Medicine, 2023, v. 20, n. 1, p. 77, doi. 10.20892/j.issn.2095-3941.2022.0612
- By:
- Publication type:
- Article
P-211: Phase 2 MARCH study: ATG-010 plus Dexamethasone in Chinese relapsed/refractory Multiple Myeloma (RRMM) patients previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S155, doi. 10.1016/S2152-2650(21)02338-7
- By:
- Publication type:
- Article
P-174: Clinical study of bortezomib-based regimens of BCD, PAD and VDD for newly diagnosed multiple myeloma – an analysis of 400 cases in a single center of China.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S131, doi. 10.1016/S2152-2650(21)02301-6
- By:
- Publication type:
- Article